Migraine Prevention is Personal to Us

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company committed to transforming migraine treatment through the discovery, development and commercialization of novel therapeutic antibodies. Our mission is to forever change migraine treatment and give people with migraine their lives back. To Alder, they are not nameless “subjects” or data points, but friends, family and others whose stories motivate us to do our best work.

Since our founding in 2004, the Alder culture has always been about perseverance and passion for developing transformative therapies to serve patients. For our patients, some we know personally, it means we work urgently on their behalf. Their crucial need for life-changing therapies drives us to deliver. We see our company as a compassionate catalyst for change.

In the past, people have had very few choices to get relief from migraines and have had to use less-than-ideal medicines that can cause unwanted side effects. Some preventive treatments, if effective, may take weeks to months to achieve meaningful clinical and quality of life benefits.1 Patients who are highly impacted and in need of preventive migraine treatments expect and deserve options that not only have an acceptable safety profile, but also provide rapid onset of prevention with strong, sustained efficacy.

We Understand Migraine

At Alder, we know that a migraine is not just a headache. We understand the profound physical and emotional toll migraine can take, and in fact, some of our employees experience it themselves. Preventing the pain and devastation of migraine is personal to all of us at Alder, therefore, we have leveraged our monoclonal antibody (mAb) expertise to design eptinezumab, our pivotal-stage mAb designed to inhibit calcitonin gene-related peptide (CGRP). If approved, eptinezumab will be the first quarterly infusion therapy for migraine prevention.

1. Parsekyan D. Migraine prophylaxis in adult patients. West J Med. 2000;173(5):341-345.